fda tirzepatide news The approved Zepbound in December 2024 for the treatment of moderate-to-severe obstructive sleep apnea in patients with obesity after research showed that the medication improved outcomes in these patients. Sleep apnea FDA approves weight-loss drug Zepbound

This includes individuals who are lean with dyslipidemia or severely obese with cardio-renal comorbidities

W.NemetI.LiX

You start at the lowest dose possible to minimize nausea and other GI side effects, and then increase gradually over weeks or months until you reach a dose that produces meaningful appetite suppression

If you have any doubts or questions about the medication, consult your healthcare provider for guidance

It Reduces Decision Fatigue Every day, you make approximately 200 decisions about food alone

"And I was like, 'I'm kind of nauseous, too.'" When the friend asked Handler if she was on Ozempic, Handler demurred, stating that she was on semaglutide